Genprex, INC. (GNPX) — 10-Q Filings

10-Q Filings (5)

• Genprex Narrows Q3 Loss, Boosts Cash from Offerings Amid Clinical Progress — Nov 14, 2025 Risk: high
  Genprex, Inc. (GNPX) reported a net loss of $3,799,240 for the three months ended September 30, 2025, a 11.97% improvement from the $4,315,987 net loss in the s
• Genprex Narrows Q2 Loss Amidst Clinical Trial Progress, Cash Declines — Aug 14, 2025 Risk: high
  Genprex, Inc. (GNPX) reported a net loss of $4,674,901 for the three months ended June 30, 2025, an improvement from a net loss of $6,495,845 in the same period
• Genprex Q1 2025 10-Q: Minimal Revenue, Assets Detailed — May 12, 2025 Risk: medium
  Genprex, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported minimal revenue for the first quarter of 2025, with $0.001 million in bo
• Genprex 10-Q: Focus on Future Funding Amidst Operating Losses — Nov 13, 2024 Risk: high
  Genprex, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported minimal revenue and significant operating losses, consistent with it
• Genprex, Inc. Q2 2024 10-Q Filing — Aug 9, 2024 Risk: medium
  Genprex, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $179,550 as of June 30, 2024. The filing details financia

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX